Datasets 81 datasets
other
16.6mfct_scmd637kstg_contracts_finder_tender_items326kfct_gp_registered_patients297kstg_cf_parties155kfct_acute_plac155kfct_acute_patient_level_activity_and_costing151kstg_procurement_contracts_finder_releases151kstg_contracts_finder_notices150kstg_cf_suppliers121kstg_cf_awards117kstg_rtt_ni_trust_specialty116kstg_foi_antidepressants_patients73kstg_did_test_to_report51kmart_rtt_incomplete_trust_monthly48kstg_innovateuk_awards46kfct_innovateuk_awards29kstg_ctgov_uk_trials25kmart_cancer_trust_monthly22kmart_ae_trust_monthly21kfct_drug_alcohol_initial_assessments_scot18kfct_older_people_sex_ratio15krq_03_trials_raw15kfct_clinical_trials13kstg_ctgov_uk_industry_interventional13kmart_percapita_trust_monthly10kstg_ctgov_industry_trials9kmap_pcn_trust7kvaccination_raw6keric_raw6kfct_gp_registered_totals4kiuk_awards_agg3kfft_raw3kfct_drug_related_hospital_statistics_scot2kgovt_funded_research2kfct_pharmacy_wales2krq02b_panel_merged2krq02b_panel2kfct_rq02b_panel_merged1kstg_rq27911_fda_510k_openfda543stg_rq27916_fda_radiology_ai403stg_rq27910_fda_ai_devices381_ingest_manifest364meta_dataset357rq27917_h_stg_openfda_510k_ai188stg_rq27916_imaging_procurement87fct_productivity_ons84scmd_monthly_national67mart_critical_care_beds_daily53isrctn_commercial_by_dimension52rq27917_vendor_clearances49rq02b_icb_bridge42rq02b_bridge_clean29ctgov_uk_industry_by_year28stg_rq27910_ai_imaging_trials26isrctn_commercial_by_year20isrctn_commercial_top_funders19rq_26_domain26_digital_maturity_dashboard__digital_maturity16rq_25298__cpv_health_tech16ingest_manifest15ctgov_uk_industry_top_sponsors15ctgov_uk_industry_top_conditions13rq16_ichp12rq16_hin_south_london12ctgov_uk_industry_by_status11rq_25299__london_icb_benchmark_seed10rq16_scorecard_add10rq16_mhra_performance8rq_25299__ahsn_spread_seed8rq_25298__ols_healthtech_companies8rq16_uclpartners8rq16_scorecard_headline8rq16_oecd_hcqi8ctgov_uk_industry_by_phase7stg_aidoc_funding6rq_25298__nhsbsa_pipeline6isrctn_commercial_results_reporting4rq_25298__contracts_health_tech4rq16_hin_network4ctgov_uk_industry_results_reporting3_t21nspl_meta
stg_ctgov_uk_industry_interventional
nhs_raw · other NHS England
13krows
199.1MBsize
34columns
2026-09-30updated
varieslicence — see publisher
Query this dataset
SELECT * FROM nhs_raw.stg_ctgov_uk_industry_interventional LIMIT 100
In-warehouse SQL · raw on S3 (limoja-nhs-warehouse) · JSON metadata · or ask the copilot
Schema
| Column | Type |
|---|---|
| nct_id | Nullable(String) |
| org_study_id | Nullable(String) |
| brief_title | Nullable(String) |
| official_title | Nullable(String) |
| overall_status | Nullable(String) |
| why_stopped | Nullable(String) |
| start_date | Nullable(String) |
| start_year | Nullable(Float64) |
| completion_date | Nullable(String) |
| first_posted | Nullable(String) |
| last_update | Nullable(String) |
| lead_sponsor_name | Nullable(String) |
| lead_sponsor_class | Nullable(String) |
| responsible_party | Tuple( type Nullable(String), oldNameTitle Nullable(String), oldOrganization Nullable(String), investigatorFullName Nullable(String), investigatorTitle Nullable(String), investigatorAffiliation Nullable(String)) |
| study_type | Nullable(String) |
| phases | Nullable(String) |
| enrollment | Nullable(Float64) |
| allocation | Nullable(String) |
| primary_purpose | Nullable(String) |
| masking | Nullable(String) |
| sex | Nullable(String) |
| minimum_age | Nullable(String) |
| maximum_age | Nullable(String) |
| healthy_volunteers | Nullable(Bool) |
| conditions | Nullable(String) |
| condition_count | Nullable(Int64) |
| intervention_count | Nullable(Int64) |
| arm_group_count | Nullable(Int64) |
| primary_outcome_count | Nullable(Int64) |
| secondary_outcome_count | Nullable(Int64) |
| location_count | Nullable(Int64) |
| has_uk_location | Nullable(Bool) |
| source_file | Nullable(String) |
| raw_json | Nullable(String) |
Sample rows
| NCT04633187 | EDP 938-103 | Effects of EDP-938 | A Phase 2b, Random | TERMINATED | Study was terminat | 2021-07-07 | 2021 | 2023-05-31 | 2020-11-18 | 2024-08-22 | Enanta Pharmaceuti | INDUSTRY | {'type': 'SPONSOR' | INTERVENTIONAL | PHASE2 | 9 | RANDOMIZED | TREATMENT | DOUBLE | ALL | 16 Years | 75 Years | False | Respiratory Syncyt | 1 | 2 | 2 | 1 | 4 | 64 | True | S001.json | {"protocolSection" |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04633187 | EDP 938-103 | Effects of EDP-938 in Hematopoietic | A Phase 2b, Randomized, Double-Blind | TERMINATED | Study was terminated due to a strate | 2021-07-07 | 2021 | 2023-05-31 | 2020-11-18 | 2024-08-22 | Enanta Pharmaceuticals, Inc | INDUSTRY | {'type': 'SPONSOR', 'oldNameTitle': | INTERVENTIONAL | PHASE2 | 9 | RANDOMIZED | TREATMENT | DOUBLE | ALL | 16 Years | 75 Years | False | Respiratory Syncytial Virus Infectio | 1 | 2 | 2 | 1 | 4 | 64 | True | S001.json | {"protocolSection":{"identificationM |
| NCT04862663 | D361DC00001 | Capivasertib + CDK4/6i + Fulvestrant | A Phase Ib/III, Open-label, Randomis | ACTIVE_NOT_RECRUITING | None | 2021-05-10 | 2021 | 2029-08-14 | 2021-04-28 | 2026-08-17 | AstraZeneca | INDUSTRY | {'type': 'SPONSOR', 'oldNameTitle': | INTERVENTIONAL | PHASE3 | 893 | RANDOMIZED | TREATMENT | NONE | ALL | 18 Years | 99 Years | False | Locally Advanced (Inoperable) or Met | 1 | 5 | 5 | 4 | 22 | 225 | True | S001.json | {"protocolSection":{"identificationM |
| NCT00160693 | C87015 | Open Label Long-Term Safety Study of | A Phase III, Multicenter, Open-Label | COMPLETED | None | 2003-03 | 2003 | 2011-02 | 2005-09-12 | 2018-08-01 | UCB Pharma | INDUSTRY | {'type': 'SPONSOR', 'oldNameTitle': | INTERVENTIONAL | PHASE3 | 402 | NA | TREATMENT | NONE | ALL | 18 Years | None | False | Rheumatoid Arthritis | 1 | 1 | 1 | 2 | 12 | 61 | True | S001.json | {"protocolSection":{"identificationM |
Cited by papers
- none yet